- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03101527
Open Trial Determining Antidepressant Effects of Omega-3 Supplementation During Pregnancy
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Pregnancy does not reduce the risk of recurrence among women who have previously experienced depressive illness and the advent of new episodes during pregnancy raises particular problems. Lingering concerns over the possible teratogenicity of medications in general leave many women reluctant to continue preexisting antidepressant prophylaxis or to accept new trials of conventional antidepressant treatment. There is also now accumulating evidence that the SSRIs have short-, and perhaps longer-term, adverse effects on the newborn.
The antidepressant effects of omega-3 polyunsaturated fatty acid (PUFA) supplementation may offer a particularly appropriate alternative to conventional therapy for depressive episodes that occur during pregnancy. The nutritional needs of the fetus increase the likelihood of omega-3 PUFA deficits in the mother but access to adequate omega-3 PUFAs through fish intake is limited due to concerns over mercury levels. Because polyunsaturated fatty acids are dietary components essential for both fetal development and maternal health, and because their use as supplementation carries a minimal to non-existent side effect burden, women may be more likely to accept omega-3 supplementation over that of conventional antidepressants to manage depressive illness if provided sufficient evidence for effectiveness.
Data supporting the antidepressant potential of omega-3 PUFA supplementation derive first from numerous case-control studies that have associated depressive illness with lower tissue concentrations of omega-3 PUFAs and with higher ratios of omega-6 to omega-3. These findings prompted antidepressant trials of omega-3 supplementation as augmentation or as mono-therapy and many reports described significant benefits over placebo, including one that targeted pregnant women and yielded a large effect size. A number of other trials, however, failed to show clear antidepressant effects. Meta-analyses have highlighted these inconsistencies in results but have found no explanations for them in differing sample demographics, baseline depressive severity levels, PUFA dosing, or trial durations. Other sources of study outcome differences undoubtedly exist and a clear possibility is that the studies with positive results involved subjects more likely to truly benefit from omega-3 supplementation. The characteristics of such individuals are entirely unknown. Though valid predictors of antidepressant response to omega-3 PUFA supplementation would provide powerful tools for personalizing treatment no study has sought to identify them.
One feature that might characterize an individual likely to respond to omega-3 PUFA supplementation is, of course, the presence of relatively low tissue concentrations of omega-3 PUFAs and/or high ratios of omega-6 to omega-3 concentrations. The likelihood that omega-3 PUFA supplementation exerts antidepressant effects via modulation of the inflammatory cascade, and the extensive evidence that high levels of pro-inflammatory markers characterize individuals with depressive disorders, indicate that these measures too may help to select those most likely to benefit from treatment with omega-3 PUFAs.
The identification of response predictors for a specific antidepressant strategy would not only have value for the selection of acute treatment for individuals with active depression but could also be used to choose preventative strategies for individuals who are not currently depressed but who are at high risk because of a recent history of a depressive episode. Prophylaxis against depressive illness in such individuals would have special importance during pregnancy. The adverse effects of depressive illness on both maternal and newborn well-being are widely appreciated but women who develop depressive disorders during pregnancy may, for a variety of reasons, fail to report symptoms to their health care provider or, if they do, treatment response may be delayed or even absent after one or more trials.
Type d'étude
Inscription (Réel)
Phase
- Première phase 1
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Women with uncomplicated pregnancy within the 1st or 2nd trimester of pregnancy
- Score of 10 or greater on the nine item Patient Health Questionnaire (PHQ-9) for depression
Exclusion Criteria:
- antidepressant use in preceding month
- use in previous 4 weeks of psychotropic medications other than hypnotics or benzodiazepines in diazepam dose-equivalents greater than or equal to 2mg/day for insomnia
- Fish allergy
- initiation of regularly scheduled course of psychotherapy within previous 2 months
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Supplementation
Subjects received Omega-3 PUFA supplementation
|
Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g docosahexaenoic daily for the duration of the study
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
The Hamilton Rating Scale for Depression (HAM-D)
Délai: Subjects were administered the HAM-D at Day 1 and every month thereafter until week 38 of their pregnancies.
|
The HAM-D is a multiple item semi-structured clinician administered questionnaire used to assess the range, type and severity of depressive symptoms observed in patients with MDD.
The HAM-D24 consists of 24 symptoms, each of which is rated from 0 to 2 or 0 to 4, where 0 is none/absent.
The HAMD-24 total score is calculated as the sum of the 24 individual symptom scores; the total score can range from 0 to 76. Higher HAMD-24 scores indicate more severe depression.
|
Subjects were administered the HAM-D at Day 1 and every month thereafter until week 38 of their pregnancies.
|
Montgomery-Asberg Depression Scale (MADRS)
Délai: Subjects were administered the MADRS on Day 1 and every month thereafter until week 38 of their pregnancies.
|
The MADRS is a clinician administered semi-structured scaled designed to detect changes in depressive symptoms.
The scale contains 10 items and ratings are graded from 0 to 6 , with 0 representing an absence of a symptom and 6 corresponding to the most severe degree of MDD symptomology.
|
Subjects were administered the MADRS on Day 1 and every month thereafter until week 38 of their pregnancies.
|
Edinburgh Postnatal Depression Scale (EPDS)
Délai: Subjects were asked to complete the EPDS on Day 1 and every month thereafter until week 38 of their pregnancies
|
The EPDS is a self-administered depression screen for postpartum women.
The EPDS consists of 10 questions.
Responses are scored 0,, 1, 2, or 3 according to increased severity of the symptom.
Items marked with an * are reversed scored.
A total score of 13 or more suggests follow-up intervention is warranted.
|
Subjects were asked to complete the EPDS on Day 1 and every month thereafter until week 38 of their pregnancies
|
Beck Depression Scale (BDI)
Délai: Subjects were asked to complete the BDI on Day 1 and every month thereafter through week 38 of their pregnancies
|
The BDI is a self-administered questionnaire developed to detect, assess, and monitor changes in depressive symptoms.
It is composed of 21 items, each with 4 possible responses scored from 0 to 3 with 3 indicating a higher level of severity.
For people who have been clinically diagnosed, scores from 0 to 9 represent minimal depressive symptoms, scores of 10 to 16 indicate mild depression, scores of 17 to 29 indicate moderate depression, and scores of 30 to 63 indicate severe depression.
|
Subjects were asked to complete the BDI on Day 1 and every month thereafter through week 38 of their pregnancies
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Publications générales
- Hibbeln JR. Seafood consumption, the DHA content of mothers' milk and prevalence rates of postpartum depression: a cross-national, ecological analysis. J Affect Disord. 2002 May;69(1-3):15-29. doi: 10.1016/s0165-0327(01)00374-3.
- De Vriese SR, Christophe AB, Maes M. Lowered serum n-3 polyunsaturated fatty acid (PUFA) levels predict the occurrence of postpartum depression: further evidence that lowered n-PUFAs are related to major depression. Life Sci. 2003 Nov 7;73(25):3181-7. doi: 10.1016/j.lfs.2003.02.001.
- Peet M, Murphy B, Shay J, Horrobin D. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry. 1998 Mar 1;43(5):315-9. doi: 10.1016/s0006-3223(97)00206-0.
- Rees AM, Austin MP, Owen C, Parker G. Omega-3 deficiency associated with perinatal depression: case control study. Psychiatry Res. 2009 Apr 30;166(2-3):254-9. doi: 10.1016/j.psychres.2007.12.011. Epub 2009 Mar 5.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 201002781
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Omega-3 PUFA supplementation
-
Coordinación de Investigación en Salud, MexicoComplétéSepticémie sévère | Syndrome de dysfonctionnement des organesMexique
-
Coordinación de Investigación en Salud, MexicoInstituto Mexicano del Seguro Social; National Council of Science and Technology...ComplétéMalnutrition | Leucémie aiguë lymphoblastiqueMexique
-
University of JenaComplétéLa polyarthrite rhumatoïdeAllemagne
-
University of JenaComplétéHypertriglycéridémieAllemagne
-
University of NottinghamUnilever R&DComplété
-
The Adelaide and Meath HospitalUniversity College DublinComplétéSyndrome des ovaires polykystiquesIrlande
-
The Adelaide and Meath HospitalUniversity College DublinComplétéSyndrome des ovaires polykystiquesIrlande
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)ComplétéTumeurs mammaires | ArthralgieÉtats-Unis
-
Federal University of Mato GrossoComplétéComplications postopératoires | Fibrillation auriculaire rapide
-
East Carolina UniversityComplétéCommotion cérébrale | Légère commotion cérébrale | Commotion cérébraleÉtats-Unis